TY - JOUR
T1 - Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD
T2 - Double-blind, randomized, controlled study
AU - Centanni, S.
AU - Santus, P.
AU - Casanova, F.
AU - Carlucci, P.
AU - Boveri, B.
AU - Castagna, F.
AU - Di Marco, F.
AU - Cazzola, M.
PY - 2002/3
Y1 - 2002/3
N2 - Anti-cholinergic agents are considered the bronchodilator therapy of first-choice in the treatment of patients with stable chronic obstructive pulmonary disease (COPD) associated with heart disease since they may be as effective or more effective than inhaled β2-agonists and, moreover, they do not interact with cardiac β-adrenoceptors. The aim of our study was to evaluate the bronchodilator activity of oxitropium bromide in outpatients suffering from exacerbations of COPD associated with heart diseases (ischaemic heart disease and/or arrhythmias).We recruited 50 consecutive outpatients (33 males and 17 females, mean age 68.6 years, 15 current smokers and 35 ex-smokers). Each patient performed body plethismography in basal condition and 30 min after inhalation of 200 μg metered dose inhaler (MDI) oxitropium bromide administered by a device (Fluspacer®), FEV1, FVC, MMEF25.75, sRaw and tRaw were evaluated. Thirty minutes after 200 μg oxitropium bromide administration, we observed a significant improvement in FEV1 11.6% ± 1 (mean ± SEM) (P <0.01); FVC, MMEF25.75 sRaw variation was respectively: 9.2% ± 0.6, 31.4 ± 2.9, -19.9 ± 1.1. Placebo did not significantly change pulmonary function. Our data suggest that oxitropium bromide bronchodilator activity is effective in exacerbations of COPD.
AB - Anti-cholinergic agents are considered the bronchodilator therapy of first-choice in the treatment of patients with stable chronic obstructive pulmonary disease (COPD) associated with heart disease since they may be as effective or more effective than inhaled β2-agonists and, moreover, they do not interact with cardiac β-adrenoceptors. The aim of our study was to evaluate the bronchodilator activity of oxitropium bromide in outpatients suffering from exacerbations of COPD associated with heart diseases (ischaemic heart disease and/or arrhythmias).We recruited 50 consecutive outpatients (33 males and 17 females, mean age 68.6 years, 15 current smokers and 35 ex-smokers). Each patient performed body plethismography in basal condition and 30 min after inhalation of 200 μg metered dose inhaler (MDI) oxitropium bromide administered by a device (Fluspacer®), FEV1, FVC, MMEF25.75, sRaw and tRaw were evaluated. Thirty minutes after 200 μg oxitropium bromide administration, we observed a significant improvement in FEV1 11.6% ± 1 (mean ± SEM) (P <0.01); FVC, MMEF25.75 sRaw variation was respectively: 9.2% ± 0.6, 31.4 ± 2.9, -19.9 ± 1.1. Placebo did not significantly change pulmonary function. Our data suggest that oxitropium bromide bronchodilator activity is effective in exacerbations of COPD.
KW - Acute exacerbation
KW - COPD
KW - Oxitropium bromide
UR - http://www.scopus.com/inward/record.url?scp=0036490679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036490679&partnerID=8YFLogxK
U2 - 10.1053/rmed.2001.1219
DO - 10.1053/rmed.2001.1219
M3 - Article
C2 - 11905547
AN - SCOPUS:0036490679
VL - 96
SP - 137
EP - 141
JO - Respiratory Medicine
JF - Respiratory Medicine
SN - 0954-6111
IS - 3
ER -